Finance

Lists
Why is NMRA down 8,07%?
Dive Deeper
NMRA:NASDAQ
Neumora Therapeutics Inc
0,44 USD
-8,07%
(-0,038) 1D
0,44 USD
+0,98% (+0,0043)
After hours
Closed: 12-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NMRA...
Open
0,48 USD
High
0,48 USD
Low
0,44 USD
Mkt. cap
81,43 млн
Avg. vol.
1,73 млн
Volume
0,00
52-wk high
3,65 USD
52-wk low
0,44 USD
EPS
-1,23 USD
Beta
2,95
Shares outstanding
187,90 млн
No. of employees
63
Open
0,48 USD
High
0,48 USD
Low
0,44 USD
Mkt. cap
81,43 млн
Avg. vol.
1,73 млн
Volume
0,00
52-wk high
3,65 USD
52-wk low
0,44 USD
EPS
-1,23 USD
Beta
2,95
Shares outstanding
187,90 млн
No. of employees
63
News stories
From web sources and news partners
About Neumora Therapeutics Inc
CEO-
Employees63
Founded2019
HeadquartersУотертаун, Массачусетс, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websiteneumoratx.com
Analyst ratings
Based on 5 analysts giving stock ratings to NMRA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for NMRA in the last 3 months.
Highest
Current 0,44 USD
7,00 USD (+1 500,73%)
Average
5,25 USD (+1 100,55%)
Lowest
4,00 USD (+814,70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
7,00 USD
+1 500,7%
08/24/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
4,00 USD
+814,7%
08/17/2026
Ami Fadia
Needham
Buy
Reiterated
5,00 USD
+1 043,4%
08/14/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/14/2026
Brian Abrahams
RBC Capital
Buy
Maintained
5,00 USD
+1 043,4%
08/14/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
05/26/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
3,00 USD
+586%
05/12/2026
Yatin Suneja
Guggenheim
Buy
Maintained
14,00 USD
+3 101,5%
05/07/2026
Last report
2026-ж., 14-авг.
Fiscal period
Q2 2026
-0,23 USD / -0,24 USD
+5,34%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
40,52 млн
44,67 млн
38,60 млн
29,28 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,18 млн
13,81 млн
14,27 млн
12,91 млн
Operating expense
52,70 млн
58,48 млн
52,86 млн
42,19 млн
Total operating expenses
52,70 млн
58,48 млн
52,86 млн
42,19 млн
Operating income
-52,70 млн
-58,48 млн
-52,86 млн
-42,19 млн
Other non operating income
7,00 миң
-269,00 миң
59,00 миң
-7,00 миң
EBT including unusual items
-56,76 млн
-59,45 млн
-53,43 млн
-43,08 млн
EBT excluding unusual items
-51,76 млн
-59,45 млн
-53,43 млн
-43,08 млн
Income tax expense
-
-
30,00 миң
-
Effective tax rate
-
-
-0,06%
-
Other operating expenses
-
-
-
-
Net income
-56,76 млн
-59,45 млн
-53,46 млн
-43,08 млн
Net profit margin
-
-
-
-
Earnings per share
-0,35
-0,35
-0,30
-0,23
Interest and investment income
1,68 млн
1,34 млн
1,23 млн
935,00 миң
Interest expense
-747,00 миң
-2,04 млн
-1,85 млн
-1,82 млн
Net interest expenses
938,00 миң
-701,00 миң
-623,00 миң
-885,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-52,68 млн
-58,47 млн
-52,86 млн
-42,18 млн
Gain or loss from assets sale
-62,00 миң
264,00 миң
-71,00 миң
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору